Part 3/6:
The oligopolistic control of insulin manufacturing by a handful of corporations has been a significant factor in affordability issues. With limited competition, these companies can set and raise prices with little fear of losing market share, making insulin prohibitively expensive for many patients who rely on it daily.
This situation has led to ongoing debates and concerns about pharmaceutical monopolies, profit motives, and the ethical implications of pricing essential medicines at levels beyond the reach of many.